Paying users zone. Data is covered by .

  • Get to Allergan PLC for $13.99, or

  • get to whole website for at least 3 months from $49.99.


Statement of Cash Flows Quarterly Data

Difficulty: Beginner

The cash flow statement provides information about a company's cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company's statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Allergan PLC, Consolidated Statement of Cash Flows (quarterly data)

USD $ in thousands

3 months ended Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013
Net income (loss)
Provision for inventory reserve
Share-based compensation
Deferred income tax benefit
Pre-tax gain sale of generics business
Non-cash tax effect of gain on sale of generics business
Goodwill impairment
In-process research and development impairments
(Gain) loss on asset sales and impairments, net
Net income impact of other-than-temporary loss on investment in Teva securities
Loss on Teva securities
Charge to settle Teva related matters
Loss on forward sale of Teva shares
Amortization of inventory step-up
Non-cash extinguishment of debt
Amortization of deferred financing costs
Contingent consideration adjustments, including accretion
Excess tax benefit from stock-based compensation
Impact of assets held for sale
Other, net
(Increase) decrease in accounts receivable, net
(Increase) decrease in inventories
(Increase) decrease in prepaid expenses and other current assets
Increase (decrease) in accounts payable and accrued expenses
Increase (decrease) in income and other taxes payable
Increase (decrease) in other assets and liabilities
Changes in assets and liabilities, net of effects of acquisitions
Reconciliation to net cash provided by operating activities
Net cash provided by operating activities
Additions to property, plant and equipment
Additions to product rights and other intangibles
Sale of generics business
Additions to investments
Proceeds from sale of investments and other assets
Payments to settle Teva related matters
Proceeds from sales of property, plant and equipment
Acquisitions of businesses, net of cash acquired
Other investing activities, net
Net cash (used in) provided by investing activities
Proceeds from borrowings of long-term indebtedness, including credit facility
Proceeds from Forward Sale of Teva securities
Debt issuance and other financing costs
Payments on debt, including capital lease obligations and credit facility
Proceeds from issuance of preferred shares
Proceeds from issuance of ordinary shares
Proceeds from stock plans
Other financing, including contingent consideration
Payments to settle Teva related matters
Repurchase of ordinary shares
Dividends paid
Excess tax benefit from stock-based compensation
Net cash provided by (used in) financing activities
Effect of currency exchange rate changes on cash and cash equivalents
Movement in cash held for sale
Net increase (decrease) in cash and cash equivalents
Source: Allergan PLC, Quarterly and Annual Reports
Item Description The company
Net cash provided by operating activities The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. Allergan PLC's net cash provided by operating activities increased from Q3 2017 to Q4 2017 but then declined significantly from Q4 2017 to Q1 2018.